What is NDC 72893-002?

72893-002 is the product NDC for Beleodaq (belinostat), Belinostat 500 mg/10mL injection, powder, lyophilized, for solution, listed with the FDA by Acrotech Biopharma Inc. It has 1 package NDC, shown above in 10- and 11-digit form.

Acrotech Biopharma Inc, NDC labeler code 72893. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Beleodaq?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Beleodaq NDC 72893-002 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72893-002Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72893-0002Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72893-002-01	7289300020172893000201	1 VIAL in 1 CARTON (72893-002-01) / 10 mL in 1 VIALMarketed from Jul 21, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Beleodaq
Generic name (nonproprietary): belinostat
Active ingredients: Belinostat — 500 mg/10mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Acrotech Biopharma IncNDC labeler code 72893
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 206256
Marketing start: Jul 21, 2014
Listing expires: Dec 31, 2026
Other FDA classes: Histone Deacetylase Inhibitors (Mechanism)
Identifiers: Product ID 72893-002_0af69daf-c3eb-436a-b8d9-8ae89c5f0c85SPL ID 0af69daf-c3eb-436a-b8d9-8ae89c5f0c85SPL set ID 2e8ef36b-71fa-4492-a16f-577d5f7d111dRxCUI 1543547, 1543552UNII F4H96P17NZUPC 0372893002011
Pharmacologic class: Histone Deacetylase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472893000201 followed by a unit qualifier and the quantity

Package 72893-0002-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 7, 2025.

Indications (excerpt from the label)

Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tu…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72893-002

What is NDC 72893-002?: 72893-002 is the product NDC for Beleodaq (belinostat), Belinostat 500 mg/10mL injection, powder, lyophilized, for solution, listed with the FDA by Acrotech Biopharma Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Beleodaq (Belinostat).
What is the active ingredient?: Belinostat.
Who is the labeler?: Acrotech Biopharma Inc, NDC labeler code 72893. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Beleodaq?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Beleodaq (Belinostat) NDC 72893-002